All News

FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon will present at upcoming drug development and investor conferences, highlighting the company’s biotechnology innovation and drug development. more »

FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon, Inc. (“Alzheon”) announced today that it has launched the roadshow for the initial public offering of its common stock. Alzheon is offering ... more »

FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon presents ALZ-801 data in oral session on the role of amyloid oligomers in Alzheimer’s Disease 10th Clinical Trials on Alzheimer’s Disease mtg. more »

FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon, Inc. published clinical results demonstrating safety profile and efficacy potential of ALZ-801 for Alzheimer’s disease. more »

FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon, Inc. announced that FDA has granted Fast Track designation to its lead clinical investigational drug, ALZ-801, for Alzheimer’s disease. more »

FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon will make three presentations at the 10th Annual Clinical Trials on Alzheimer’s Disease (CTAD) congress to be held on November 1‐4 in Boston. more »

FRAMINGHAM, Mass.--(EON: Enhanced Online News)--Alzheon will be making keynote and featured presentations at several scientific, business and drug development conferences in the Fall. more »